Daniel Lingwood

Dr. Daniel Lingwood

The Ragon Institute of MGH, MIT and Harvard, Cambridge, MA 02139, USA
orcid

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 December 2021 in Science Immunology
Verified
Journal Article
Closed access
MSMurillo Silva
Murillo Silva
YKYu Kato
Yu Kato
MMMariane Bandeira Melo
Mariane Bandeira Melo
IPIvy Phung
Ivy Phung
BFBrian L. Freeman
Brian L. Freeman
DIDarrell J. Irvine
Darrell J. Irvine
An adjuvant composed of saponin and a TLR4 agonist acts by enhancing lymph flow and antigen entry into lymph nodes.

1 October 2019 in Immunity
Verified
Journal Article
Closed access
MSMaya Sangesland
Maya Sangesland
LRLarance Ronsard
Larance Ronsard
SKSamuel W. Kazer
Samuel W. Kazer
JBJulia Bals
Julia Bals
SBSeyhan Boyoglu-Barnum
Seyhan Boyoglu-Barnum
DLDaniel Lingwood
Daniel Lingwood

30 January 2024 in Nature Communications
Verified
Journal Article
Open access
PDF file
EWEike-Christian Wamhoff
Eike-Christian Wamhoff
LRLarance Ronsard
Larance Ronsard
JFJared Feldman
Jared Feldman
GKGrant A. Knappe
Grant A. Knappe
BHBlake M. Hauser
Blake M. Hauser
MBMark Bathe
Mark Bathe
Protein-based virus-like particles (P-VLPs) are commonly used to spatially organize antigens and enhance humoral immunity through multivalent antigen display. However, P-VLPs are thymus-dependent antigens that are themselves immunogenic and can induce B cell responses that may neutralize the platform. Here, we investigate thymus-independent DNA origami as an alternative material for multivalent antigen display using the receptor binding domain (RBD) of the SARS-CoV-2 spike protein, the primary target of neutralizing antibody responses. Sequential immunization of mice with DNA-based VLPs (DNA-VLPs) elicits protective neutralizing antibodies to SARS-CoV-2 in a manner that depends on the valency of the antigen displayed and on T cell help. Importantly, the immune sera do not contain boosted, class-switched antibodies against the DNA scaffold, in contrast to P-VLPs that elicit strong B cell memory against both the target antigen and the scaffold. Thus, DNA-VLPs enhance target antigen immunogenicity without generating scaffold-directed immunity and thereby offer an important alternative material for particulate vaccine design.

1 December 2020 in Cell Systems
Verified
Journal Article
Closed access
AAAssaf Amitai
Assaf Amitai
MSMaya Sangesland
Maya Sangesland
RBRalston M. Barnes
Ralston M. Barnes
DRDaniel Rohrer
Daniel Rohrer
NLNils Lonberg
Nils Lonberg
ACArup K. Chakraborty
Arup K. Chakraborty

10 December 2021 in Science Immunology
Verified
Journal Article
Open access
JFJared Feldman
Jared Feldman
JBJulia Bals
Julia Bals
CAClara G. Altomare
Clara G. Altomare
KDKerri St. Denis
Kerri St. Denis
ELEvan C. Lam
Evan C. Lam
ASAaron G. Schmidt
Aaron G. Schmidt
Naive antibodies targeting the SARS-CoV-2 receptor binding domain can be isolated from SARS-CoV-2 seronegative individuals.

7 January 2016 in Nature Protocols
Verified
Journal Article
Closed access
PDF file
GWGrant C Weaver
Grant C Weaver
RVRina F Villar
Rina F Villar
MKMasaru Kanekiyo
Masaru Kanekiyo
GNGary J Nabel
Gary J Nabel
JMJohn R Mascola
John R Mascola
DLDaniel Lingwood
Daniel Lingwood